# Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

> **NCT04556461** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. Stephan Weidinger** · enrollment: 16 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab

## Key facts

- **NCT ID:** NCT04556461
- **Lead sponsor:** Prof. Dr. Stephan Weidinger
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-03-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04556461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04556461, "Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04556461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*